NCT04921930 (ARTEMIS) is a Phase 1, PHASE2 clinical trial of Artesunate Oral Product in Friedreich Ataxia, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

Who is sponsoring NCT04921930?

NCT04921930 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

What drugs are being tested in NCT04921930?

Interventions in NCT04921930: Artesunate Oral Product.

What condition does NCT04921930 study?

NCT04921930 studies Friedreich Ataxia.

Is NCT04921930 still recruiting?

NCT04921930 is currently completed. Last updated 30 July 2024.

Last reviewed 2024-07-30 · How we verify

NCT04921930: ARTEMIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)

Completed Phase 1, PHASE2 Last updated 30 July 2024

What this trial tests

Phase 1, PHASE2 trial testing Artesunate Oral Product in Friedreich Ataxia in 20 participants. Completed in 17 April 2024.

Timeline

6 May 2022

Primary endpoint
17 April 2024

17 April 2024

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	6 May 2022
Primary completion	17 April 2024
Estimated completion	17 April 2024
Sites	1 location across France

Drugs / interventions tested

Artesunate Oral Product — full drug profile →

Conditions studied

Friedreich Ataxia — all drugs for Friedreich Ataxia →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

Adults 16 to 65, male only, with Friedreich Ataxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of Friedreich ataxia. It will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial diseases: from molecular mechanisms to therapeutic advances.
Wen H, Deng H, Li B, Chen J, et al · · 2025 · cited 111× · PMID 39788934 · DOI 10.1038/s41392-024-02044-3
Drug Repositioning in Friedreich Ataxia.
Rufini A, Malisan F, Condò I, Testi R. · · 2022 · cited 10× · PMID 35221903 · DOI 10.3389/fnins.2022.814445

Verify or expand the search:

Other recruiting trials for Friedreich Ataxia

Currently open trials in the same condition.

NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07508631 — Friedreich Ataxia Nerve Ultrasund · recruiting
NCT06953583 — A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich' · Phase 3 · recruiting
NCT06623890 — A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who · recruiting
NCT06054893 — A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participa · Phase 1 · recruiting

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04921930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
Last refreshed: 30 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04921930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing